MoonLake Immunotherapeutics (MLTX) has a consensus analyst rating of Buy, based on 18 analysts covering the stock. Of those, 14 recommend buying, 2 recommend holding, and 2 recommend selling.
The analyst consensus price target for MLTX is $25.25, representing a +34.5% upside from the current price of $18.78. Price targets range from a low of $10.00 to a high of $35.00.
